Equities research analysts expect OpGen, Inc. (NASDAQ:OPGN) to announce sales of $910,000.00 for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for OpGen’s earnings. The lowest sales estimate is $750,000.00 and the highest is $1.06 million. OpGen reported sales of $1.01 million in the same quarter last year, which would suggest a negative year over year growth rate of 9.9%. The company is expected to announce its next quarterly earnings report on Thursday, March 22nd.

On average, analysts expect that OpGen will report full-year sales of $910,000.00 for the current fiscal year, with estimates ranging from $2.97 million to $3.71 million. For the next fiscal year, analysts expect that the business will report sales of $6.70 million per share, with estimates ranging from $3.39 million to $10.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover OpGen.

A number of equities research analysts recently issued reports on the stock. HC Wainwright set a $1.00 target price on shares of OpGen and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Zacks Investment Research upgraded shares of OpGen from a “hold” rating to a “buy” rating and set a $0.25 price objective for the company in a research report on Tuesday, August 15th.

An institutional investor recently bought a new position in OpGen stock. Perkins Capital Management Inc. acquired a new position in shares of OpGen, Inc. (NASDAQ:OPGN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,400,000 shares of the medical research company’s stock, valued at approximately $434,000. Perkins Capital Management Inc. owned about 2.72% of OpGen at the end of the most recent reporting period. Institutional investors own 10.90% of the company’s stock.

OpGen (NASDAQ:OPGN) traded up $0.01 during trading hours on Tuesday, hitting $0.28. 426,100 shares of the stock were exchanged, compared to its average volume of 1,136,185. OpGen has a one year low of $0.21 and a one year high of $3.10. The company has a quick ratio of 0.19, a current ratio of 0.29 and a debt-to-equity ratio of -0.55.

ILLEGAL ACTIVITY NOTICE: “OpGen, Inc. (OPGN) Expected to Post Quarterly Sales of $910,000.00” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/14/opgen-inc-opgn-expected-to-post-quarterly-sales-of-910000-00.html.

OpGen Company Profile

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.